Ausgabe 6/2017
Inhalt (20 Artikel)
Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells
Joana Liberal, Anália Carmo, Célia Gomes, Maria Teresa Cruz, Maria Teresa Batista
Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
Mohamed Wehbe, Cody Lo, Ada W. Y. Leung, Wieslawa H. Dragowska, Gemma M. Ryan, Marcel B. Bally
Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells
Anusha Chidambaram, Arunachalam Sekar, Kavya S.H., Ramesh Kumar Chidambaram, Kalaiarasi Arunachalam, Senthilkumar G.P., Ravikumar Vilwanathan
Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A
Ariane Chan, Connie Gilfillan, Nikki Templeton, Ian Paterson, Peter T. Northcote, John H. Miller
Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors
Miodrag Dragoj, Jasna Bankovic, Evangelia Sereti, Sofija Jovanovic Stojanov, Konstantinos Dimas, Milica Pesic, Tijana Stankovic
Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity
Hyo Jeong Lee, Bo-Kyoung Kim, Kyoung Bin Yoon, Yong-Chul Kim, Sun-Young Han
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M. Smyth, Kelsey R. Monson, Komal Jhaveri, Alexander Drilon, Bob T. Li, Wassim Abida, Gopa Iyer, John F. Gerecitano, Mrinal Gounder, James J. Harding, Martin H. Voss, Vicky Makker, Alan L. Ho, Pedram Razavi, Alexia Iasonos, Philip Bialer, Mario E. Lacouture, Jerrold B. Teitcher, Joseph P. Erinjeri, Nora Katabi, Matthew G. Fury, David M. Hyman
Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
Lotte van Andel, Z. Zhang, S. Lu, V. Kansra, S. Agarwal, L. Hughes, M. M. Tibben, A. Gebretensae, L. Lucas, M. J. X. Hillebrand, H. Rosing, J. H. M. Schellens, J. H. Beijnen
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
A. Stathis, D. Hess, R. von Moos, K. Homicsko, G. Griguolo, M. Joerger, M. Mark, C. J. Ackermann, S. Allegrini, C. V. Catapano, A. Xyrafas, M. Enoiu, S. Berardi, P. Gargiulo, C. Sessa
A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors
Gun Min Kim, Tony Reid, Sang Joon Shin, Sun Young Rha, Joong Bae Ahn, Sung Sil Lee, Hyun Cheol Chung
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
Su Jin Lee, Seon Young Lee, Weon Sup Lee, Jin San Yoo, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Myung-Ju Ahn, Ho Yeong Lim, Won Ki Kang, Young Suk Park
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
Junichiro Watanabe, Yoshinori Ito, Shozo Ohsumi, Mitsuhiro Mizutani, Hideya Tashiro, Kenichi Sakurai, Masato Takahashi, Tsuyoshi Saito, Junji Tsurutani, Hirofumi Mukai, Tetsuhiro Yoshinami, Shintaro Takao, Yasuhisa Yamamoto, Toshiyuki Matsuoka, Hirotaka Iwase, Hiroji Iwata, Seigo Nakamura, Toshiaki Saeki
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations
Kosei Hasegawa, Masahiro Kagabu, Mika Mizuno, Katsutoshi Oda, Daisuke Aoki, Seiji Mabuchi, Shoji Kamiura, Satoshi Yamaguchi, Yoichi Aoki, Toshiaki Saito, Mayu Yunokawa, Kazuhiro Takehara, Aikou Okamoto, Kazunori Ochiai, Tadashi Kimura
Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial
Anish B. Parikh, Peter Kozuch, Nicholas Rohs, Daniel J. Becker, Benjamin P. Levy
Mechanisms of cancer cell killing by sea cucumber-derived compounds
Teresa Liliana Wargasetia, Widodo
Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications
D. Shepshelovich, H. Goldvaser, L. Wang, A. R. Abdul Razak, P. L. Bedard
Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials
Meihui Cao, Feifei Li, Yue Wang, Jingdong Zhang
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Nobuaki Mamesaya, Hirotsugu Kenmotsu, Toshiaki Takahashi
Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients
Valentine Heidelberger, François Goldwasser, Nora Kramkimel, Anne Jouinot, Nathalie Franck, Jennifer Arrondeau, Sarah Guégan, Audrey Mansuet-Lupo, Jérôme Alexandre, Diane Damotte, Marie-Françoise Avril, Nicolas Dupin, Sélim Aractingi
Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer
Tomoyoshi Takenaka, Koji Yamazaki, Naoko Miura, Naohiko Harada, Sadanori Takeo